Pediatric Nintedanib Dosing
For children and adolescents aged 6-17 years with fibrosing interstitial lung disease, nintedanib should be dosed using weight-based allometric scaling, with the InPedILD trial demonstrating that this approach achieves similar drug exposure to the adult 150 mg twice daily regimen while maintaining an acceptable safety profile 1.
Weight-Based Dosing Regimen
The pediatric dosing is not a simple mg/kg calculation but rather uses weight-dependent allometric scaling to achieve target drug exposure comparable to adults 1, 2. The InPedILD trial established that:
- Ages 6-11 years: Weight-based dosing achieved geometric mean AUCτ,ss of 175 µg·h·L⁻¹ (85.1% geometric coefficient of variation)
- Ages 12-17 years: Weight-based dosing achieved geometric mean AUCτ,ss of 160 µg·h·L⁻¹ (82.7% geometric coefficient of variation)
These exposures are similar to those seen in adults receiving the standard 150 mg twice daily dose 1.
Critical caveat: The exact weight-based dosing table is not provided in the available evidence, but the trial used body weight-dependent allometric scaling with single-step dose reductions permitted to manage adverse events 2.
Hepatic Impairment Adjustments
Pediatric-specific hepatic impairment dosing has not been established. However, extrapolating from adult data 3:
- Mild hepatic impairment (Child-Pugh A): Nintedanib exposure increases approximately 2-fold. Close monitoring is required with dose adjustment as needed
- Moderate hepatic impairment (Child-Pugh B): Nintedanib exposure increases approximately 8-fold. Not recommended in this population
- Severe hepatic impairment: Contraindicated (no data available)
The adult guideline recommends monitoring liver function tests monthly for 3 months, then every 3 months 4.
Dose Modifications for Adverse Effects
Diarrhea Management
- Incidence: 38.5% in pediatric patients on nintedanib vs 15.4% on placebo 1
- Action: Single-step dose reduction permitted 2
- Monitoring: Watch for weight loss 4
Hepatotoxicity Management
- Monitoring schedule:
- Monthly LFTs for first 3 months
- Every 3 months thereafter 4
- Action for elevated transaminases:
- Dose reduction or temporary interruption
- Female patients have 3-4 fold higher risk of liver enzyme elevations compared to males at equivalent exposures 5
Treatment Discontinuation
In the InPedILD trial, only 2 patients discontinued nintedanib due to adverse events out of 26 treated, suggesting good overall tolerability with dose management 1.
Key Monitoring Parameters
Baseline and ongoing:
- Liver function tests (ALT, AST, bilirubin)
- Body weight (for dose adjustments)
- Gastrointestinal symptoms assessment
- Pulmonary function (FVC% predicted) 2
Important Clinical Considerations
- Administration: Should be given with food (extrapolated from adult recommendations)
- Eligibility criteria from trial: FVC ≥25% predicted, evidence of fibrosis on HRCT, clinically significant disease 2
- Contraindications: Underlying chronic liver disease, significant pulmonary arterial hypertension, cardiovascular disease, or increased bleeding risk 2
- Drug interactions: Avoid potent P-glycoprotein inhibitors or inducers, which can significantly alter nintedanib exposure 6
The pediatric data provides a scientific basis for nintedanib use in children and adolescents with fibrosing ILD, though this represents emerging evidence from a single trial 1.